Cantor Fitzgerald reiterates Zai Lab stock rating on ADC potential

Cantor Fitzgerald reiterated Overweight on Zai Lab with a $37 price target; shares were up 45% year-to-date and recently traded at $25.62. Merck’s withdrawal of a competing B7-H3 ADC may improve the positioning of Zai Lab’s zocilurtatug, but Cantor said response rates of 70%–80% and median progression-free survival near seven months are largely priced in, with more than eight months potentially needed for meaningful upside. Zai Lab also beat second-quarter estimates, reporting adjusted EPS of -$0.05 versus -$0.60 expected and revenue of $106.3 million versus $104.34 million.

Analysis

The investable signal is a change in competitive opportunity, not validation of zocilurtatug: a rival program’s withdrawal may open a lane, but it does not establish efficacy, safety, durability, or approval probability. With the shares already sharply rerated, the key near-term asymmetry is clinical-data sensitivity. If ESMO results merely meet the response and PFS profile described as largely priced in, the vacant-competitor narrative may not support further multiple expansion; a median PFS above eight months could improve the upside case, but small early cohorts and immature follow-up can make apparent differentiation fragile. Over 1–3 months, focus on data quality—patient count, confidence intervals, duration of response, and combination-specific toxicity—not headline response rate. Over 6–18 months, first-line development and ZL-1503 are optionality, not yet a basis for underwriting near-term revenue. A contrarian risk is that investors treat one competitor’s exit as category validation when it may instead reflect difficult biology or development economics. The supplied headline references Samsung/Goldman while the body concerns Zai Lab; verify the source before acting. The reference to Merck is not sufficient to assign the event to the mapped MRK security.

Key Decisions for Investors

• Do not chase ZLAB solely on the competitor-withdrawal narrative after the reported rally. Until trial details and valuation inputs are independently checked, treat it as a catalyst watch rather than a high-conviction entry.
• If taking exposure ahead of the ESMO readout, size it as event risk and prefer defined-risk structures over unhedged options; option pricing and liquidity are missing, so no specific structure or premium is recommended.
• For a post-data long, require evidence beyond response rate: median PFS around or above the stated eight-month hurdle, credible follow-up, and acceptable safety. Weak durability, wide uncertainty, or material toxicity would falsify the differentiated-leadership thesis.
• Track first-line cohort updates and ZL-1503 safety/pharmacokinetics separately; neither should be capitalized as near-term earnings without reproducible clinical evidence. Reassess if timelines slip or data fail to support progression into the next study.